Social media hub

As the Asia-Pacific (APAC) region continues to emerge as a key player in the biosimilar sector, it presents significant opportunity for market entry and expansion. In our latest blog on this region, we explore critical...

With no universal standard, designing Delphi panels can be complex—but also incredibly valuable. ICON’s Patient-Centred Outcomes experts share practical strategies for tailoring Delphi designs to support expert consensus...

Multi-indication development is now central to cardiometabolic drug pipelines. A 2025 ICON survey shows 83% of developers engage in multi-indication therapies. What commercialisation strategies are they employing? Explor...